Journal Article

Clinical Impact of GB Virus C Viremia on Patients with HIV Type 1 Infection in the Era of Highly Active Antiretroviral Therapy

Wang-Huei Sheng, Chien-Ching Hung, Ruei-Jiuan Wu, Jann-Tay Wang, Pei-Jer Chen, Shan-Chwen Chang and Jia-Horng Kao

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 44, issue 4, pages 584-590
Published in print February 2007 | ISSN: 1058-4838
Published online February 2007 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/511037
Clinical Impact of GB Virus C Viremia on Patients with HIV Type 1 Infection in the Era of Highly Active Antiretroviral Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Background. The influence of GB virus C (GBV-C) viremia on clinical outcomes of patients with human immunodeficiency virus type 1 (HIV-1) infection remains controversial in the era of highly active antiretroviral therapy (HAART).

Methods. A prospective observational study was conducted to describe the epidemiology of GBV-C viremia and assess its clinical impact on treatment responses to HAART in 385 HIV-1–infected patients during the period from January 1999 through June 2004.

Results. A total of 59 patients (15.3%) had detectable GBV-C RNA viremia during a median observation of 3.6 years (range, 1.0–7.0 years); 47 patients (12.2%) had GBV-C viremia at enrollment, and 12 (3.1%) acquired GBV-C infection during follow-up. Thirty-two (68.1%) of the 47 patients with baseline GBV-C viremia had persistent GBV-C viremia. Compared with patients with clearance of GBV-C viremia (n = 15) and patients without detectable GBV-C viremia (n = 326), patients with persistent GBV-C viremia were more likely to be men who have sex with men (81.3% vs. 60.4%; P = .02), tended to have lower baseline plasma HIV RNA load (HIV RNA load ≥5 log10 copies/mL, 31.3% vs. 49.4%; P = .05), and had a higher proportion of isolated anti—hepatitis B core antibody (37.5% vs. 17.2%; P = .005). There was no statistically significant difference in terms of virologic, immunologic, and clinical responses to HAART; occurrence of hepatic events; and mortality among the 3 groups.

Conclusions. Persistent GBV-C viremia is significantly associated with male-male sex in HIV-infected patients with advanced immunodeficiency, and persistent GBV-C viremia does not confer short-term benefit in patients receiving HAART.

Journal Article.  3953 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.